ABIONYX
Developing of novel therapies for the treatment of cardiovascular and metabolic diseases.
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 678 % | (12 %) | (2 %) | 6 % | 38 % | 182 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (844 %) | (76 %) | (67 %) | (89 %) | (248 %) | (234 %) | (52 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (863 %) | (80 %) | (76 %) | (96 %) | (257 %) | (246 %) | (59 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 730 % | 21 % | 33 % | 42 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
ABIONYX Pharma is a cutting-edge biotech company focused on discovering and developing innovative therapies for patients who currently lack effective treatment options. The company operates in the biotechnology sector, specifically targeting cardiovascular diseases and associated metabolic disorders such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). ABIONYX also explores HDL-targeted drug delivery platforms in the field of oncology, particularly immuno-oncology. The business model involves leveraging existing development assets inherited from CERENIS Therapeutics and forming strategic partnerships to advance its research and development activities. ABIONYX generates revenue through the development and commercialization of its proprietary therapies and drug delivery platforms.
Keywords: biotech, cardiovascular diseases, metabolic disorders, NAFLD, NASH, HDL-targeted, drug delivery, oncology, immuno-oncology, innovative therapies.
Tech stack
Investments by ABIONYX
Edit